BEONE MEDICINES LTD-ADR (ONC) Stock News

USA - Nasdaq - NASDAQ:ONC - US07725L1026 - ADR

347.72 USD

-1.57 (-0.45%)

Last: 11/21/2025, 8:00:02 PM

347.72 USD

0 (0%)

After Hours: 11/21/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ONC Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: BeOne Medicines Ltd.

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

5 days ago - By: Benzinga - Mentions: JAZZ ZYME

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

5 days ago - By: BeOne Medicines Ltd.

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

16 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

16 days ago - By: Zacks Investment Research

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

16 days ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

25 days ago - By: BeOne Medicines Ltd.

BeOne Medicines to Present at Upcoming Investor Conferences

4 months ago - By: The Motley Fool

BeOne Medicines (ONC) Q2 EPS Soars 924%

26 days ago - By: The Motley Fool - Mentions: PPTA STNE XP NU

Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally

a month ago - By: BeOne Medicines Ltd.

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

a month ago - By: BeOne Medicines Ltd.

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

a month ago - By: BeOne Medicines Ltd.

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

2 months ago - By: Investor's Business Daily - Mentions: PFE NYT LLY ZLAB ...

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

3 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

3 months ago - By: Yahoo Finance

BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025

3 months ago - By: BeOne Medicines Ltd.

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

3 months ago - By: BeOne Medicines Ltd.

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

3 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

3 months ago - By: BeOne Medicines Ltd.

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

4 months ago - By: Zacks Investment Research

BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

4 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

4 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia

4 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

4 months ago - By: Yahoo Finance

BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra